35969-75-6

Basic information

• Product Name: 3-NITRO-6-PYRIDINECARBOXALDEHYDE
• Synonyms: 3-NITRO-6-PYRIDINECARBOXALDEHYDE;5-NITRO-2-PYRIDINECARBOXALDEHYDE;5-Nitropyridine-2-carboxaldehyde;5-Nitro-2-forMylpyridine;5-Nitro-2-pyridinecarbaldehyde;5-nitropyridine-2-carbaldehyde;5-Nitropicolinaldehyde
• CAS NO: 35969-75-6
• Molecular Formula: C₆H₄N₂O₃
• Molecular Weight: 152.11
• EINECS: 200-258-5
• Mol File: 35969-75-6.mol
• Article Data: 14

Chemical Properties

• Melting Point: 54-57℃
• Boiling Point: 298.7°Cat760mmHg
• Flash Point: 134.5°C
• Appearance: /
• Density: 1.432±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.627
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.31±0.10(Predicted)
• CAS DataBase Reference: 3-NITRO-6-PYRIDINECARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-NITRO-6-PYRIDINECARBOXALDEHYDE(35969-75-6)
• EPA Substance Registry System: 3-NITRO-6-PYRIDINECARBOXALDEHYDE(35969-75-6)

Safety Data

• Statements: 43
• Safety Statements: 36/37
• Hazardous Substances Data: 35969-75-6(Hazardous Substances Data)

Usage

Uses

5-Nitropyridine-2-carbaldehyde is used in the synthetic preparation of pyridine-2-carboxaldehyde thiosemicarbazone which has antitumor activity.

InChI:InChI=1/C6H4N2O3/c9-4-5-1-2-6(3-7-5)8(10)11/h1-4H

Upstream product

• 30651-24-2 5-nitropicolinic acid 
• 4487-59-6 2-bromo-5-nitropyridine 
• 29682-14-2 5-nitro-pyridine-2-carboxylic acid methyl ester 
• 60891-70-5 1,3-diethyl 2-(5-nitropyridin-2-yl)propanedioate 
• 4548-45-2 2-chloro-5-nitropyridine 
• 30563-98-5 ethyl 5-nitropyridine-2-carboxylate 
• 21203-68-9 2-methyl-5-nitropyridine 

Downstream Products

• 1402045-96-8 N-(5-nitropyridin-2-ylmethyl)-N-pyridin-2-ylmethylbenzamide 
• 1402045-97-9 N-(5-aminopyridin-2-ylmethyl)-N-pyridin-2-ylmethylbenzamide 
• 36625-57-7 (5-nitropyridin-2-yl)methanol 
• 1419605-14-3 phenyl (6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)carbamate 
• 1419605-16-5 1-((3-tert-butyl-1-(3-fluorophenyl)-1H-pyrazol-5-yl)methyl)-3-(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)urea 
• 1419601-80-1 1-((3-tert-butyl-1-(3-fluorophenyl)-1H-pyrazol-5-yl)methyl)-3-(6-(hydroxymethyl)pyridin-3-yl)urea 

Relevant articles and documents

AKT3 MODULATORS

Compounds of Formula la, lb, or Ic, are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 in vitro or in vivo, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

5-HETEROARYL SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, Darier's disease, scleroderma, cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as neurological conditions/disorders/diseases linked to overexpression of DYRK1A.

5-SUBSTITUTED INDAZOLE-3-CARBOXAMIDES AND PREPARATION AND USE THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease, fibrotic disorders, cartilage (chondral) defects, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, and neurological conditions/disorders/diseases linked to overexpression of DYRK1A.